tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Mediastinal Diseases D008477 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Protoporphyria, Erythropoietic D046351 1 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Lacerations D022125 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Guy S et al. Immunosuppression conversion for relief of side effects. 1994 Transplant. Proc. pmid:7527956
Gibbs JF et al. Outcome analysis of FK 506 therapy for acute and chronic rejection. 1993 Transplant. Proc. pmid:7679823
Nomoto S et al. Cardiotoxicity of long-term intravenous administration of FK506 in rabbits: dose relationship and recovery after discontinuance. 1994 Transplant. Proc. pmid:7513477
Scheel AK et al. Severe neurotoxicity of tacrolimus (FK506) after renal transplantation: two case reports. 2001 Nov-Dec Transplant. Proc. pmid:11750573
Siekierka JJ et al. Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. 1991 Transplant. Proc. pmid:1721256
Satomura K et al. Pharmacokinetics of FK 506 in living-related liver transplantation. 1996 Transplant. Proc. pmid:8623209
Morris-Stiff G et al. Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. 1998 Transplant. Proc. pmid:9636525
Wang XH et al. Tacrolimus vs CyA Neoral in combination with MMF and steroids after cadaveric renal transplantation. 2000 Transplant. Proc. pmid:11119899
Burke GW et al. Cholesterol control: long-term benefit of pancreas-kidney transplantation with FK 506 immunosuppression. 1998 Transplant. Proc. pmid:9532153
Aravot D et al. A new immunosuppressive protocol for lung transplantation: early promising results. 2003 Transplant. Proc. pmid:12644072
Gallego-Valcarce E et al. Conversion to tacrolimus extended-release formulation: short-term clinical results. 2009 Jul-Aug Transplant. Proc. pmid:19715909
Molleví DG et al. Late xenograft rejection: comparison between liver and heart xenografts under low-dose tacrolimus. 2002 Transplant. Proc. pmid:11959212
Cimsit B et al. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. 2011 Transplant. Proc. pmid:21486625
Zhao Y et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. 2005 Jan-Feb Transplant. Proc. pmid:15808586
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Chan KL et al. Porcine small bowel transplantation with FK506 as a single immunosuppressant. 2001 Transplant. Proc. pmid:11406260
Charpentier B An induction versus no-induction protocol in anticalcineurin-based immunosuppression using very low-dose steroids. 2001 Transplant. Proc. pmid:11406262
Rilo HR et al. Effect of intraportal human islet transplantation on kidney graft survival in simultaneous kidney-islet allografts. 1993 Transplant. Proc. pmid:7680172
Fukuzaki T et al. Induction of unresponsiveness to islet allograft by preoperative donor spleen cell injection and FK 506 treatment. 1993 Transplant. Proc. pmid:7680173
Blanc P et al. Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. 1991 Transplant. Proc. pmid:1721288
Ueno M et al. Immunosuppressive effect in combination therapy of cyclosporine A, FK 506, and 15-deoxyspergualin on pancreatic islet xenotransplantation. 1992 Transplant. Proc. pmid:1373546
Loréal O et al. FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. 1991 Transplant. Proc. pmid:1721289
Matsuzaki T et al. Liver transplantation for diethylnitrosamine-induced hepatocellular carcinoma in rats. 1992 Transplant. Proc. pmid:1373547
D'Silva M et al. Immunosuppressive effect of RS-61443 on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623467
Platz KP et al. Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation. 1998 Transplant. Proc. pmid:9636596
Moriuchi H et al. Mechanisms of immunosuppressive effects of FK 506 in light of apoptosis of hepatocytes and infiltrating lymphocytes in rat allografted livers. 2000 Transplant. Proc. pmid:11120182
Ghobrial RM et al. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. 1998 Transplant. Proc. pmid:9636597
Oliveira DB and Chang R Report of the first 118 tacrolimus-treated patients at St George's Hospital, London. 1999 Transplant. Proc. pmid:10576047
Tian JH et al. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials. 2009 Transplant. Proc. pmid:19917365
Hatori M et al. Clinicopathologic examination of no-episode biopsies in well-functioning renal allografts. 1998 Transplant. Proc. pmid:9474971
San Segundo D et al. Study of B-cell subpopulations in lung transplant recipients with posttransplant infection. 2012 Transplant. Proc. pmid:23146491
Egawa H et al. Lymphoproliferative disorders in patients undergoing living-related liver transplantation. 1998 Transplant. Proc. pmid:9474982
Tanabe K et al. Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid. 2004 Transplant. Proc. pmid:15518791
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Demetris AJ et al. Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. 1993 Transplant. Proc. pmid:7505503
Todo S et al. Intestinal transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7518136
Woodle ES et al. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease. 1993 Transplant. Proc. pmid:7682360
Lang T et al. Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. 1995 Transplant. Proc. pmid:7533367
Chen-Woan M et al. Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721320
Ziolkowski J et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. 2003 Transplant. Proc. pmid:14529923
Ushigome H et al. Pediatric living-related renal transplantation under tacrolimus as the primary immunosuppressive agent. 2003 Transplant. Proc. pmid:12591350
Nakamura Y et al. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy. 2005 Transplant. Proc. pmid:15919445
Furukawa H and Todo S Evolution of immunosuppression in liver transplantation: contribution of cyclosporine. 2004 Transplant. Proc. pmid:15041353
Ogino S et al. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients. 2004 Transplant. Proc. pmid:15041357
Junge G et al. Microchimerism in patients after orthotopic liver transplantation: a prognostic indicator? 2002 Transplant. Proc. pmid:12176475
Kumano K et al. Role of endothelin in FK 506-induced renal hypoperfusion in rats. 1995 Transplant. Proc. pmid:7533423
Orlandi V et al. Tacrolimus-associated myositis: a case report in a renal transplant patient. 2004 Transplant. Proc. pmid:15110639
Kilian K et al. FK-506 (tacrolimus) therapy for an unusual SLE-like disease. 1998 Transplant. Proc. pmid:9865322
Green M et al. Infectious complications of pediatric liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721352
de Oliveira Clark RM et al. Evaluation of hemodynamic, metabolic, and electrolytic changes after graft reperfusion in a porcine model of intestinal transplantation. 2010 Jan-Feb Transplant. Proc. pmid:20172287
Fischereder M et al. Gynaecomastia following solid organ transplantation. 2002 Transplant. Proc. pmid:12270376
Hohage H et al. Switching immunosuppression from cyclosporine to tacrolimus improves long-term kidney function: a 6-year study. 2005 Transplant. Proc. pmid:15919497
Perego C et al. Orthotopic liver-small bowel transplantation in pigs: study of immunologic parameters during therapy with FK 506-based immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907908
Budde K et al. Five year outcome of tacrolimus rescue therapy in late rejection after renal transplantation. 2002 Transplant. Proc. pmid:12176499
Malaise J et al. Corticosteroid withdrawal in simultaneous pancreas-kidney transplantation: a 3-year report. 2005 Jul-Aug Transplant. Proc. pmid:16182832
Soylu H et al. Survival of renal transplant patients: data from a tertiary care center in Turkey. 2015 Transplant. Proc. pmid:25769571
Karakulska-Prystupiuk E et al. Pericarditis in Patients With Chronic Graft-vs-Host Disease. 2018 Transplant. Proc. pmid:30177139
Hara Y et al. Heterotopic rat heart transplantation to the iliac vessels. 1994 Transplant. Proc. pmid:7520632
Nishimura Y et al. A trial to obtain donor-specific immunotolerance using a vascularized thymus allograft. 1998 Transplant. Proc. pmid:9838684
McCauley J et al. Changes in renal function after liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721385
Damotte D et al. Morphologic features of large bowel biopsies in combined small and large bowel transplantations could predict clinical rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083252
Ota H et al. Intrathymic microchimerism predicts rejection response in allograft recipients. 1997 Feb-Mar Transplant. Proc. pmid:9123279
Tashiro H et al. Correlation of high-level microchimerism with graft acceptance in rat liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123287
Paul LC Overview of side effects of immunosuppressive therapy. 2001 Transplant. Proc. pmid:11377462
Kiuchi T et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. 1996 Transplant. Proc. pmid:8962229
Rodrigo E et al. Histopathological findings according to Banff-97 classification system comparing tacrolimus versus cyclosporine. 2002 Transplant. Proc. pmid:12176550
Ierardi E et al. Long-term tacrolimus: a promising therapeutic approach for Crohn's disease. 2001 Transplant. Proc. pmid:11377467
Guckelberger O et al. Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation? 1996 Transplant. Proc. pmid:8962230
Hatakeyama S et al. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients. 2012 Transplant. Proc. pmid:22310594
Mori T et al. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies. 2007 Transplant. Proc. pmid:17580201
Ishibashi M et al. Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max). 2001 Feb-Mar Transplant. Proc. pmid:11266958
Fukuzaki T et al. Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. 1991 Transplant. Proc. pmid:1721415
Degawa H et al. Blocking of ICAM-1 and LFA-1 in rat liver transplantation. 1996 Transplant. Proc. pmid:8658695
Braun N et al. Impairment of renal function following liver transplantation. 2003 Transplant. Proc. pmid:12826191
Van Buren D et al. Impact of Sandimmune, Neoral, and Prograf on rejection incidence and renal function in primary liver transplant recipients. 1998 Transplant. Proc. pmid:9723299
Taber DJ et al. Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. 2000 Transplant. Proc. pmid:10812156
El-Sabrout R et al. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience. 2003 Transplant. Proc. pmid:12742474
Testillano M et al. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center. 2009 Transplant. Proc. pmid:19376421
Jiménez-Pérez M et al. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation. Transplant. Proc. pmid:25645779
Polanco N et al. Everolimus-based immunosuppression therapy for BK virus nephropathy. Transplant. Proc. pmid:25645770
Filler G et al. One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion. 2002 Transplant. Proc. pmid:12176634
Tinti F et al. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients. 2010 Transplant. Proc. pmid:21168623
Shaffer D et al. Calcineurin inhibitor avoidance versus steroid avoidance following kidney transplantation: Postoperative complications. 2006 Transplant. Proc. pmid:17175304
Staak A et al. Immunoglobulin induction therapy in renal transplant recipients: Effects on immunoglobulin and regulatory antibody levels. 2006 Transplant. Proc. pmid:17175311
Neff GW et al. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. 2003 Transplant. Proc. pmid:14697970
Martín-Fernández M et al. Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. 2017 Transplant. Proc. pmid:29149986
Fabrega AJ et al. FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. 1991 Transplant. Proc. pmid:1721447
Winkler M et al. Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation. 1993 Transplant. Proc. pmid:7689277
Moreno M et al. Clinical management of tacrolimus drug interactions in renal transplant patients. 1999 Transplant. Proc. pmid:10500564
Viebahn R et al. Simulation of hypoxic and preservation injury in human hepatocyte cultures: influence of FK 506 and cyclosporine. 1993 Transplant. Proc. pmid:7689278
Tur MD et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. 2000 Transplant. Proc. pmid:11134804
Dé P et al. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3? 1993 Transplant. Proc. pmid:7689279
Kanbay M et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. 2005 Transplant. Proc. pmid:16213325
Mita A et al. Optimal initial dose of orally administered once-daily extended-release tacrolimus following intravenous tacrolimus therapy after liver transplantation. 2014 Transplant. Proc. pmid:24767351
Wojarski J et al. Immunosuppressive Treatment and Its Effect on the Occurrence of Pneumocystis jiroveci, Mycoplasma pneumoniae, Chlamydophila pnemoniae, and Legionella pneumophila Infections/Colonizations Among Lung Transplant Recipients. 2018 Transplant. Proc. pmid:30177108
Preston R et al. FK 506 as primary immunosuppressive therapy in renal transplantation. 1998 Transplant. Proc. pmid:9636493
Tamura S et al. Conversion to cyclosporine provides valuable rescue therapy for living donor adult liver transplant patients intolerant to tacrolimus: A single-center experience at the University of Tokyo. 2004 Transplant. Proc. pmid:15686738
Kanatani T et al. Experimental limb transplantation, part III: induction of tolerance in the rigorous strain combination of Brown Norway donor to Lewis recipient. 2004 Transplant. Proc. pmid:15686745
Dallos G et al. Results and complications after living related kidney transplantation in Hungary: 30 years' experience. 2010 Jul-Aug Transplant. Proc. pmid:20692470
Szabó L et al. Effect of tacrolimus on the excitatory synaptic transmission between the parallel fibers and pyramidal cells in the rat dorsal cochlear nucleus. 2010 Jul-Aug Transplant. Proc. pmid:20692476